MLICM
NRIX icon

Metropolitan Life Insurance Company (MetLife)’s Nurix Therapeutics NRIX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,703
Closed -$39.7K – 1401
2024
Q1 		$39.7K Hold
2,703
– – ﹤0.01% 1523
2023
Q4 		$27.9K Hold
2,703
– – ﹤0.01% 1769
2023
Q3 		$21.2K Hold
2,703
– – ﹤0.01% 1865
2023
Q2 		$27K Buy
+2,703
New +$27.6K ﹤0.01% 1770
2023
Q1 		– Sell
-2,703
Closed -$29.7K – 2415
2022
Q4 		$29.7K Hold
2,703
– – ﹤0.01% 1797
2022
Q3 		$35.2K Hold
2,703
– – ﹤0.01% 1695
2022
Q2 		$34.2K Buy
2,703
+575
+27% +$6.52K ﹤0.01% 1734
2022
Q1 		$29.8K Sell
2,128
-6,891
-76% -$122K ﹤0.01% 1889
2021
Q4 		$261K Hold
9,019
– – ﹤0.01% 1829
2021
Q3 		$270K Buy
+9,019
New +$278K ﹤0.01% 1860
2021
Q2 		– Sell
-6,951
Closed -$216K – 2819
2021
Q1 		$216K Buy
6,951
+3,458
+99% +$131K ﹤0.01% 1967
2020
Q4 		$115K Hold
3,493
– – ﹤0.01% 2296
2020
Q3 		$122K Buy
+3,493
New +$88K ﹤0.01% 2105

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s NRIX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Nurix Therapeutics (NRIX) in Q2 2024, closing a stake of 2,703 shares — an estimated $39.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in NRIX in Q3 2020 and held it in 13 quarters. The position peaked at $270K in Q3 2021. 173 funds tracked by Wall St. Rank hold NRIX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Nurix Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 2,703 Nurix Therapeutics shares in Q2 2024, an estimated $39.7K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Nurix Therapeutics in Q3 2020 and held it in 13 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Nurix Therapeutics position peaked at $270K in Q3 2021.
  • 173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.